Cargando…

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing

SIMPLE SUMMARY: Myelofibrosis is a heterogeneous disease regarding its mutation landscape as well as its clinical presentation and outcome. A genomic classification with prognostic implications of myeloproliferative neoplasms has been previously proposed, however, this classification has hardly been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garrote, Marta, López-Guerra, Mónica, Arellano-Rodrigo, Eduardo, Rozman, María, Carbonell, Sara, Guijarro, Francesca, Santaliestra, Marta, Triguero, Ana, Colomer, Dolors, Cervantes, Francisco, Álvarez-Larrán, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417554/ https://www.ncbi.nlm.nih.gov/pubmed/37568719 http://dx.doi.org/10.3390/cancers15153904

Ejemplares similares

P1054: CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING
por: Garrote Ordeig, Marta, et al.
Publicado: (2023)

P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS
por: Garrote, M., et al.
Publicado: (2022)

Novel Tools for Diagnosis and Monitoring of AML
por: Guijarro, Francesca, et al.
Publicado: (2023)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Chronic lymphocytic leukemia and prolymphocytic leukemia. Two coins or two sides of the same coin?
por: Magnano, Laura, et al.
Publicado: (2020)

Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
por: García-Fortes, María, et al.
Publicado: (2022)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
por: Mosquera-Orgueira, Adrián, et al.
Publicado: (2022)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes
por: Castaño-Díez, Sandra, et al.
Publicado: (2022)

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping
por: Díaz-González, Álvaro, et al.
Publicado: (2023)

How I treat splenomegaly in myelofibrosis
por: Cervantes, F
Publicado: (2011)

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis
por: Visani, Giuseppe, et al.
Publicado: (2023)

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria
por: Rumi, Elisa, et al.
Publicado: (2017)

Esophageal Variceal Hemorrhage Secondary to Post-Polycythemic Myelofibrosis
por: Motomura, Douglas, et al.
Publicado: (2018)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome
por: Guijarro, Francesca, et al.
Publicado: (2023)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

P1039: PALPABLE SPLEEN SIZE IS PROGNOSTIC IN PRIMARY BUT NOT SECONDARY MYELOFIBROSIS
por: Lucijanic, M., et al.
Publicado: (2022)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

P1040: FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS
por: Bankar, Aniket, et al.
Publicado: (2023)

P986: CYTOGENETIC DIAGNOSIS WITH NEXT-GENERATION CYTOGENETICS BY OPTICAL GENOME MAPPING IN PATIENTS WITH MYELOFIBROSIS.
por: Díaz González, Á., et al.
Publicado: (2022)

Generalized lymphadenopathy secondary to isolated extramedullary hematopoiesis as an initial manifestation of primary myelofibrosis
por: Aljabry, Mansour S., et al.
Publicado: (2018)

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
por: Huang, J., et al.
Publicado: (2022)

Classification of the agricultural frontier of Mexico in accordance with the slope
por: Tovar Cabañas, Rodrigo, et al.
Publicado: (2022)

Murine Models of Myelofibrosis
por: Jacquelin, Sebastien, et al.
Publicado: (2020)

Fibrocytes in primary myelofibrosis
por: Shimoda, Kazuya, et al.
Publicado: (2021)

The Role of Navitoclax in Myelofibrosis
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Osteolytic lesions in myelofibrosis
por: Johnson, Isla, et al.
Publicado: (2021)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Novel therapeutics for myelofibrosis
por: Lee, Sung-Eun
Publicado: (2023)

Captopril mitigates splenomegaly and myelofibrosis in the Gata1 (low) murine model of myelofibrosis
por: Corey, Seth J., et al.
Publicado: (2018)

Circulating megakaryocyte in primary myelofibrosis: an uncommon finding in a myelofibrosis blood smear
por: Cantó, Pedro Asensi, et al.
Publicado: (2021)

Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case
por: Sugiura, Hiroyuki, et al.
Publicado: (2020)

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
por: Ferrer-Marín, Francisca, et al.
Publicado: (2013)

Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life
por: Fiz, Jimena, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_abgdo5uqk5fv9476as23aks4a3